3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Advanced Cancer
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Non-Muscle Invasive Bladder Neoplasms
1
Melanoma
1
Lymphoid Interstitial Pneumonia
1
Laryngeal Diseases
1
Endometrial Adenocarcinoma
1
Carcinoma, Squamous Cell
1
Advanced Gastric Cancer
1
Interventions
relatlimab
2
linrodostat
2
Nivolumab
2
Ipilimumab
2
Vorinostat
1
Trastuzumab
1
IFL protocol
1
Gemcitabine
1
Dasatinib
1
Cetuximab
1
BMS-813160
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Cancer
×
linrodostat
×
Clear all
NCT02996110
2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2
Completed
182 enrolled
23 charts
NCT02750514
2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2
Terminated
295 enrolled
21 charts